Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

PURPOSE: Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in combination with endocrine therapy for the treatment of women and men with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC). In the phase 2, open-l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Finn, Richard S., Boer, Katalin, Bondarenko, Igor, Patel, Ravindranath, Pinter, Tamas, Schmidt, Marcus, Shparyk, Yaroslav V., Thummala, Anu, Voitko, Nataliia, Bananis, Eustratios, McRoy, Lynn, Wilner, Keith, Huang, Xin, Kim, Sindy, Slamon, Dennis J., Ettl, Johannes
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7383036/
https://ncbi.nlm.nih.gov/pubmed/32683565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05755-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados